Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GMALL-OBECEL study of Obe-cel for MRD-positive Ph-negative B-precursor ALL in first complete remission
2025-524169-26-00Phase 2Authorised
- Sponsor
- Goethe University Frankfurt
- Start
- Jul 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obecabtagene autoleucel in acute lymphoblastic leukemia (ALL), sponsored by Goethe University Frankfurt. Primary endpoint: Event-free survival at 12 months. Planned start Jul 2026; status: authorised.
02
Drugs
obecabtagene autoleucel
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2025-524169-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524169-26-00.